Form 4 for CALC CalciMedica, Inc.
Accepted 2023-10-10 00:00:00 ET · period of report 2023-03-20 · accession 0001209191-23-052521 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2023-10-10 | 2023-03-20 | CALC | Sanderling Ventures VII, L.P. | 10% | A - Grant | — | +936.7K | 14.4K | New | — |
| D | 2023-10-10 | 2023-03-20 | CALC | Sanderling Ventures VII, L.P. | 10% | A - Grant | — | +703.4K | 703.4K | New | — |
| DMI | 2023-10-10 | 2023-03-20 | CALC | Sanderling Ventures VII, L.P. | 10% | A - Grant | — | +52.5K | 8,393 | New | — |
| DM | 2023-10-10 | 2023-03-20 | CALC | Sanderling Ventures VII, L.P. | 10% | A - Grant | — | +21.9K | 2,672 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-20 | A | A | 17,682 | — | 17,682 | I By Sanderling VI Beteligungs GmbH & Co KG | — | — | (F3) Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 2 | Common | Common Stock | 2023-03-20 | A | A | 7,456 | — | 7,456 | I By Sanderling VI Limited Partnership | — | — | (F4) Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 3 | Common | Common Stock | 2023-03-20 | A | A | 8,884 | — | 8,884 | I By Sanderling Ventures VII, L.P. | — | — | (F5) Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 4 | Common | Common Stock | 2023-03-20 | A | A | 240,676 | — | 240,676 | I By Sanderling Ventures VII Annex Fund, L.P. | — | — | (F6) Received in exchange for 8,356,779 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 5 | Common | Common Stock | 2023-03-20 | A | A | 582,757 | — | 582,757 | I By Sanderling Ventures Management VI | — | — | (F2) Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 6 | Common | Common Stock | 2023-03-20 | A | A | 63,228 | — | 63,228 | I By Sanderling Ventures Management VII | — | — | (F8) Received in exchange for 2,195,354 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 7 | Common | Common Stock | 2023-03-20 | A | A | 1,548 | — | 1,548 | I | — | — | (F10) Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement. |
| 8 | Common | Common Stock | 2023-03-20 | A | A | 703,388 | — | 703,388 | D By Sanderling Venture Partners VI Co-Investment Fund, L.P. | — | — | (F1) Received in exchange for 24,423,158 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. |
| 9 | Common | Common Stock | 2023-03-20 | A | A | 14,425 | — | 14,425 | I By Sanderling Ventures VII (Canada), L.P. | — | — | (F7) Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement. (F9) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 10 | Derivative | Warrant | 2023-03-20 | A | A | 237 | — | 237 | I By Sanderling Ventures VII, LP | $27.94 · — to 2026-03-04 | 237 Common Stock | (F18) Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 11 | Derivative | Warrant | 2023-03-20 | A | A | 183 | — | 183 | I By Sanderling Ventures VII (Canada), LP | $27.94 · — to 2026-06-25 | 183 Common Stock | (F19) Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 12 | Derivative | Warrant | 2023-03-20 | A | A | 15,403 | — | 15,403 | I By Sanderling Ventures VII, LP | $27.94 · — to 2026-06-25 | 15,403 Common Stock | (F17) Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 13 | Derivative | Warrant | 2023-03-20 | A | A | 6,852 | — | 6,852 | I By Sanderling Ventures Management VI | $27.94 · — to 2026-02-22 | 6,852 Common Stock | (F16) Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 14 | Derivative | Warrant | 2023-03-20 | A | A | 1,910 | — | 1,910 | I By Sanderling Ventures Management VI | $26.74 · — to 2027-02-28 | 1,910 Common Stock | (F15) Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 15 | Derivative | Warrant | 2023-03-20 | A | A | 2,685 | — | 2,685 | D By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $27.94 · — to 2026-06-25 | 2,685 Common Stock | (F14) Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 16 | Derivative | Warrant | 2023-03-20 | A | A | 16,539 | — | 16,539 | D By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $27.94 · — to 2026-02-22 | 16,539 Common Stock | (F13) Received in exchange for a warrant to purchase 574,269 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 17 | Derivative | Warrant | 2023-03-20 | A | A | 2,672 | — | 2,672 | D By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $26.74 · — to 2027-02-28 | 2,672 Common Stock | (F12) Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 18 | Derivative | Warrant | 2023-03-20 | A | A | 167 | — | 167 | I | $27.94 · — to 2026-06-25 | 167 Common Stock | (F27) Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 19 | Derivative | Warrant | 2023-03-20 | A | A | 113 | — | 113 | I | $27.94 · — to 2026-03-04 | 113 Common Stock | (F26) Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 20 | Derivative | Warrant | 2023-03-20 | A | A | 840 | — | 840 | I | $27.94 · — to 2026-06-25 | 840 Common Stock | (F25) Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 21 | Derivative | Warrant | 2023-03-20 | A | A | 569 | — | 569 | I By Sanderling Ventures Management VII | $27.94 · — to 2026-03-04 | 569 Common Stock | (F24) Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 22 | Derivative | Warrant | 2023-03-20 | A | A | 3,249 | — | 3,249 | I By Sanderling Ventures Management VII | $27.94 · — to 2026-06-25 | 3,249 Common Stock | (F23) Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 23 | Derivative | Warrant | 2023-03-20 | A | A | 2,203 | — | 2,203 | I By Sanderling Ventures VII Annex Fund, L.P. | $27.94 · — to 2026-03-04 | 2,203 Common Stock | (F22) Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 24 | Derivative | Warrant | 2023-03-20 | A | A | 12,380 | — | 12,380 | I By Sanderling Ventures VII Annex Fund, L.P. | $27.94 · — to 2026-06-25 | 12,380 Common Stock | (F21) Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |
| 25 | Derivative | Warrant | 2023-03-20 | A | A | 8,393 | — | 8,393 | I By Sanderling Ventures VII (Canada), LP | $27.94 · — to 2026-02-22 | 8,393 Common Stock | (F20) Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F11) Immediately exercisable. |